Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Davis K. L., Thal L. J., Gamzu E. R., Davis C. S., Woolson R. F., Gracon S. I., Drachman D. A., Schneider L. S., Whitehouse P. J., Hoover T. M. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. N Engl J Med. 1992 Oct 29;327(18):1253–1259. doi: 10.1056/NEJM199210293271801. [DOI] [PubMed] [Google Scholar]
- Knapp M. J., Knopman D. S., Solomon P. R., Pendlebury W. W., Davis C. S., Gracon S. I. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA. 1994 Apr 6;271(13):985–991. [PubMed] [Google Scholar]
- Levy R., Eagger S., Griffiths M., Perry E., Honavar M., Dean A., Lantos P. Lewy bodies and response to tacrine in Alzheimer's disease. Lancet. 1994 Jan 15;343(8890):176–176. doi: 10.1016/s0140-6736(94)90966-0. [DOI] [PubMed] [Google Scholar]
- Nakano I., Hirano A. Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease. Ann Neurol. 1984 May;15(5):415–418. doi: 10.1002/ana.410150503. [DOI] [PubMed] [Google Scholar]
- Ott B. R., Lannon M. C. Exacerbation of parkinsonism by tacrine. Clin Neuropharmacol. 1992 Aug;15(4):322–325. doi: 10.1097/00002826-199208000-00008. [DOI] [PubMed] [Google Scholar]
- Wilcock G. K., Scott M. I. Tacrine for senile dementia of Alzheimer's or Lewy body type. Lancet. 1994 Aug 20;344(8921):544–544. doi: 10.1016/s0140-6736(94)91933-x. [DOI] [PubMed] [Google Scholar]